0001140361-24-025064.txt : 20240509 0001140361-24-025064.hdr.sgml : 20240509 20240509083522 ACCESSION NUMBER: 0001140361-24-025064 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240509 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240509 DATE AS OF CHANGE: 20240509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: FEMASYS INC CENTRAL INDEX KEY: 0001339005 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 113713499 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40492 FILM NUMBER: 24928771 BUSINESS ADDRESS: STREET 1: 3950 JOHNS CREEK COURT STREET 2: SUITE 100 CITY: SUWANEE STATE: GA ZIP: 30024 BUSINESS PHONE: 770-500-3910 MAIL ADDRESS: STREET 1: 3950 JOHNS CREEK COURT STREET 2: SUITE 100 CITY: SUWANEE STATE: GA ZIP: 30024 8-K 1 ef20028745_8k.htm 8-K
 UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 9, 2024

Femasys Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-40492
11-3713499
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)

3950 Johns Creek Court, Suite 100
Suwanee, Georgia
  
30024
(Address of principal executive offices)
  
(Zip Code)

(770) 500-3910
(Registrant’s telephone number, including area code)

n/a
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each class
  
Trading
Symbol(s)
  
Name of each
exchange
on which registered
Common Stock, par value $0.001 per share
  
FEMY
  
The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 2.02
Results of Operations and Financial Condition.

On May 9, 2024, Femasys Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2024 and provided a corporate update. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
 
The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
 
Item 9.01
Financial Statements and Exhibits.
(d)
Exhibits.

Exhibit
No.
Description
   
Press Release of Femasys Inc. dated May 9, 2024
104
Cover Page Interactive Data File (embedded within the Inline XBRL Document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
Femasys Inc.
   
 
By:
/s/ Kathy Lee-Sepsick
 
Names:
Kathy Lee-Sepsick
 
Title:
Chief Executive Officer
   
Date: May 9, 2024
  


EX-99.1 2 ef20028745_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1

Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update
 
-- Recruitment of the commercial team for our infertility portfolio and the pivotal trial of FemBloc® for permanent non-surgical birth control continues --
 
ATLANTA, May 9, 2024 -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the quarter ended March 31, 2024 and provides a corporate update.
 
Corporate Highlights from 1Q 2024 to date
 

 •
Company announced positive topline data from pivotal trial for FDA-cleared FemaSeed® for the treatment of infertility.

•
Company announced the first in-office commercial procedure with FDA-cleared FemaSeed infertility solution at a former investigative site.

•
Appointed Richard Spector as Chief Commercial Officer.

•
Initiated enrollment in pivotal trial (NCT05977751) of our permanent birth control candidate FemBloc at two academic sites, for a total of six active sites, the maximum permitted in the first stage.
 
“Femasys is well positioned to commercialize our infertility portfolio, led by FemaSeed in 2024 with promising top line data from the FemaSeed pivotal trial that was more than double the historic intrauterine insemination (IUI) pregnancy rates for male factor infertility (i.e., low sperm count). We are focused on completing recruitment of the commercial team and ramping up commercial operations, while continuing to support enrollment in our pivotal trial for FemBloc, our proprietary solution for permanent non-surgical birth control,” said Femasys’ CEO Kathy Lee-Sepsick. “We believe we have sufficient cash to fund operations into the second half of 2025, allowing us to continue our track record of achieving our stated milestones and moving our mission forward to deliver innovative purposely engineered solutions for women’s health that are safe, effective, accessible, and affordable.”
 
Financial Results for Quarter Ended March 31, 2024
 

 •
Research and development expenses increased by $233,292 to $1,770,731 in Q1 of 2024 from $1,537,439 in Q1 of 2023

•
Sales decreased by $22,844 to $271,140 in Q1 of 2024 from $293,984 in Q1 of 2023

•
Net loss was $3,599,510 or $0.17 per basic and diluted share attributable to common stockholders, for the quarter ended March 31, 2024, compared to net loss of $2,946,257, or $0.25 per basic and diluted share attributable to common stockholders, for the quarter ended March 31, 2023
 

 •
Cash and cash equivalents as of March 31, 2024 was $17,835,968 and the Company had an accumulated deficit of $111,981,139. The Company expects, based on its current operating plan, that its existing cash and cash equivalents will be sufficient to fund its ongoing operations into the second half of 2025
 
For more information, please refer to the Company’s Form 10-Q filed May 9, 2024, which can be accessed on the SEC website.
 
FEMASYS INC.
Condensed Balance Sheets
(unaudited)

Assets
  
March 31,
 2024
    
December 31,
2023
  
Current assets:
            
Cash and cash equivalents
  
$
17,835,968
      
21,716,077
  
Accounts receivable, net
    
120,529
      
98,906
  
Inventory, net
    
971,297
      
667,118
  
Prepaid and other current assets
    
955,539
      
695,879
  
Total current assets
    
19,883,333
      
23,177,980
  
Property and equipment, at cost:
                
Leasehold improvements
    
1,212,417
      
1,212,417
  
Office equipment
    
47,308
      
47,308
  
Furniture and fixtures
    
417,654
      
414,303
  
Machinery and equipment
    
2,582,220
      
2,559,356
  
Construction in progress
    
569,723
      
423,077
  
     
4,829,322
      
4,656,461
  
Less accumulated depreciation
    
(3,615,405
)
    
(3,545,422
)
Net property and equipment
    
1,213,917
      
1,111,039
  
Long-term assets:
                
Lease right-of-use assets, net
    
2,227,561
      
2,380,225
  
Intangible assets, net of accumulated amortization
    
33,115
      
—
  
Other long-term assets
    
1,013,034
      
1,086,581
  
Total long-term assets
    
3,273,710
      
3,466,806
  
Total assets
  
$
24,370,960
      
27,755,825
  
(continued)
                
 
FEMASYS INC.
Condensed Balance Sheets
(unaudited)
 
Liabilities and Stockholders’ Equity
  
March 31,
2024
    
December 31,
2023
  
Current liabilities:
            
Accounts payable
  
$
1,095,730
      
1,137,823
  
Accrued expenses
    
673,457
      
1,444,296
  
Clinical holdback – current portion
    
93,376
      
65,300
  
Lease liabilities – current portion
    
494,967
      
406,636
  
Total current liabilities
    
2,357,530
      
3,054,055
  
Long-term liabilities:
                
Clinical holdback – long-term portion
    
30,389
      
54,935
  
Convertible notes payable, net (including related parties)
    
4,472,456
      
4,258,179
  
Lease liabilities – long-term portion
    
1,902,991
      
2,036,067
  
Total long-term liabilities
    
6,405,836
      
6,349,181
  
Total liabilities
    
8,763,366
      
9,403,236
  
Commitments and contingencies
                
Stockholders’ equity:
                
Common stock, $.001 par, 200,000,000 authorized, 22,216,570 shares issued and 22,099,347 outstanding as of March 31, 2024; and 21,774,604 shares issued and 21,657,381 outstanding as of December 31, 2023
    
22,217
      
21,775
  
Treasury stock, 117,223 common shares
    
(60,000
)
    
(60,000
)
Warrants
    
2,631,838
      
2,787,137
  
Additional paid-in-capital
    
124,994,678
      
123,985,306
  
Accumulated deficit
    
(111,981,139
)
    
(108,381,629
)
Total stockholders’ equity
    
15,607,594
      
18,352,589
  
Total liabilities and stockholders' equity
  
$
24,370,960
      
27,755,825
  
 
FEMASYS INC.
Condensed Statements of Comprehensive Loss
(unaudited)

   
Three Months Ended March 31,
  
   
2024
    
2023
  
Sales
  
$
271,140
      
293,984
  
Cost of sales (excluding depreciation expense)
    
88,532
      
105,120
  
                 
Operating expenses:
                
Research and development
    
1,770,731
      
1,537,439
  
Sales and marketing
    
300,487
      
244,896
  
General and administrative
    
1,502,804
      
1,315,137
  
Depreciation and amortization
    
71,228
      
133,066
  
Total operating expenses
    
3,645,250
      
3,230,538
  
Loss from operations
    
(3,462,642
)
    
(3,041,674
)
Other income (expense):
                
Interest income
    
224,684
      
97,089
  
Interest expense
    
(361,552
)
    
(1,672
)
Total other income (expense)
    
(136,868
)
    
95,417
  
Net loss
  
$
(3,599,510
)
    
(2,946,257
)
                 
Net loss attributable to common stockholders, basic and diluted
  
$
(3,599,510
)
    
(2,946,257
)
Net loss per share attributable to common stockholders, basic and diluted
  
$
(0.17
)
    
(0.25
)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted
    
21,775,357
      
11,872,255
  
 
About Femasys
 
Femasys is a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions, including a lead revolutionary product candidate and FDA-cleared products. FemaSeed® Intratubal Insemination, an innovative infertility treatment designed to deliver sperm directly where conception occurs, is FDA-cleared and has received regulatory approval in Canada. FemBloc® permanent birth control in late-stage clinical development is the first and only non-surgical, in-office, permanent birth control method intended to be a safer option for women at substantially less cost than the long-standing surgical alternative. The Company has developed diagnostic products that are complementary for which it has achieved regulatory approvals to market in the U.S., Canada, and other ex-U.S. territories, and which are commercial-ready due to its in-house manufacturing capabilities. Its diagnostic products include FemVue® for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath®, an intrauterine catheter for selective fallopian tube evaluation, and FemCerv®, an endocervical tissue sampler for cervical cancer diagnosis. Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.
 
Forward-Looking Statements
 
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to develop and advance our current product candidates and programs into, and successfully initiate, enroll and complete, clinical trials; the ability of our clinical trials to demonstrate safety and effectiveness of our product candidates and other positive results; estimates regarding the total addressable market for our products and product candidates; our ability to commercialize our products and product candidates, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.

Contacts:
 
Investors:
Gene Mannheimer
IR@femasys.com

Media Contact:
Kati Waldenburg
Media@femasys.com


 EX-101.SCH 3 femy-20240509.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 femy-20240509_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Ex Transition Period Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 femy-20240509_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Document and Entity Information
May 09, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 09, 2024
Entity File Number 001-40492
Entity Registrant Name Femasys Inc.
Entity Central Index Key 0001339005
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 11-3713499
Entity Address, Address Line One 3950 Johns Creek Court
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Suwanee
Entity Address, State or Province GA
Entity Address, Postal Zip Code 30024
City Area Code 770
Local Phone Number 500-3910
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol FEMY
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period true
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 24 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://femasys.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports ef20028745_8k.htm femy-20240509.xsd femy-20240509_lab.xml femy-20240509_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ef20028745_8k.htm": { "nsprefix": "femy", "nsuri": "http://femasys.com/20240509", "dts": { "inline": { "local": [ "ef20028745_8k.htm" ] }, "schema": { "local": [ "femy-20240509.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "labelLink": { "local": [ "femy-20240509_lab.xml" ] }, "presentationLink": { "local": [ "femy-20240509_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 30, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://femasys.com/role/DocumentAndEntityInformation", "longName": "000100 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c20240509to20240509", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20028745_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240509to20240509", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20028745_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001140361-24-025064-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-24-025064-xbrl.zip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end XML 17 ef20028745_8k_htm.xml IDEA: XBRL DOCUMENT 0001339005 2024-05-09 2024-05-09 false 0001339005 8-K 2024-05-09 Femasys Inc. DE 001-40492 11-3713499 3950 Johns Creek Court Suite 100 Suwanee GA 30024 770 500-3910 false false false false Common Stock, par value $0.001 per share FEMY NASDAQ true true